drugset / Trial / NCT00721695

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

NCT00721695

Phase 1/2 Completed 60 enrolled Omeros Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

This is an exploratory study to determine the safety and clinical benefit of OMS302 Injection in subjects undergoing Cataract Extraction with Lens Replacement (CELR) using a coaxial phacoemulsification process.

Timeline

Start
2008-05
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject OMS302 Unknown Other
Comparator OMS302-PE Unknown

Indications